drugset
Drugs / TDENV-F17
last change Apr 2018 re-read 3 minutes ago

TDENV-F17

also known as Tetravalent dengue virus, live, attenuated vaccine, TDENV-F17

Vaccine

Developed for
dengue disease
Investigated by
GlaxoSmithKline · U.S. Army Medical Research and Development Command · Walter Reed Army Institute of Research (WRAIR)

Trials 1

today NCT03110952 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03110952 Jan 2016 → Apr 2017 dengue disease U.S. Army Medical Research and Development Command Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TDENV-F17 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110952 ↗
Known as Tetravalent dengue virus, live, attenuated vaccine, TDENV-F17 “Tetravalent dengue virus, live, attenuated vaccine, TDENV-F17” NCT03110952 ↗
Modality Vaccine “Tetravalent dengue virus, live, attenuated vaccine, TDENV-F17” NCT03110952 ↗